RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTCBB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, announced today that the United States Patent and Trademark Office issued a patent assigned to PolyMedix relating to angiogenesis inhibitors. The patent, number 7,553,876, entitled “Polycationic Compounds and Uses Thereof,” relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis.
